TP53 and acute myeloid leukemia: The TP53 tumor suppressor gene is frequently inactivated in cancers by loss-of-function or missense DNA binding domain mutations, seen in almost 50% of tumors [82,83], in up to 15% of overall AML cases, and in 25% of elderly cases [84].